The burden of bleeding in haemophilia: Is one bleed too many?

Haemophilia

Volumn 20, Issue 4, 2014, Pages 459-463

  Gringeri, A ^a   Ewenstein, B ^b   Reininger, A ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Haemarthrosis; Haemophilia; Joint bleeding prophylaxis; Quality of life

Indexed keywords

BLEEDING; CARTILAGE; HEALTH CARE COST; HEMOPHILIA; HUMAN; IN VITRO STUDY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SYNOVIUM; COMPLICATION; HEMOPHILIA A; HEMORRHAGE; JOINT DISEASES;

CARTILAGE; HEMOPHILIA A; HEMORRHAGE; HUMANS; JOINT DISEASES; QUALITY OF LIFE;

EID: 84904719468     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12375     Document Type: Review

References (46)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
3. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895-902.
4. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
5. Perrin JM, MacLean WE Jr, Janco RL, Gortmaker SL. Stress and incidence of bleeding in children and adolescents with hemophilia. J Pediatr 1996; 128: 82-8.
6. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
7. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
8. National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed November 4, 2007.
9. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl. 3): 117-21.
10. Jansen NW, Roosendaal G, Wenting MJ et al. Very rapid clearance after a joint bleed in the canine knee cannot prevent adverse effects on cartilage and synovial tissue. Osteoarthritis Cartilage 2009; 17: 433-40.
11. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143: 632-40.
12. Forsyth AL, Rivard GE, Valentino LA et al. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond. Haemophilia 2012; 18(Suppl. 4): 112-9.
13. Sen D, Chapla A, Walter N, Daniel V, Srivastava A, Jayandharan GR. Nuclear factor (NF)-kappaB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia. J Thromb Haemost 2013; 11: 293-306.
14. Roosendaal G, Jansen NWD, Schutgens R, Lafeber FPJG. Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment. Haemophilia 2008; 14(Suppl. 6): 4-10.
15. Roosendaal G, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Cartilage damage as a result of hemarthrosis in a human in vitro model. J Rheumatol 1997; 24: 1350-4.
16. Roosendaal G, Vianen ME, Marx JJ, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: a human in vitro study. Arthritis Rheum 1999; 42: 1025-32.
17. Jansen NW, Roosendaal G, Bijlsma JW, Degroot J, Lafeber FP. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum 2007; 56: 199-207.
18. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
19. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
20. Funk MB, Schmidt H, Becker S et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002; 8: 98-103.
21. Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
22. Lundin B, Ljung R, Pettersson H. MRI scores of ankle joints in children with haemophilia-comparison with clinical data. Haemophilia 2005; 11: 116-22.
23. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11: 438-43.
24. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-73.
25. Fischer K, Steen Carlsson K, Petrini P et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-36.
26. Lundin B, Babyn P, Doria AS et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11: 109-15.
27. Pettersson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70: 565-70.
28. Brown SA, Aledort LM, Lee CA. Optimal treatment regimens for patients with bleeding disorders. Haemophilia 2001; 7: 313-20.
29. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
30. den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15: 83-90.
31. Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia 2012; 18: 369-74.
32. Kraft J, Blanchette V, Babyn P et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012; 10: 2494-502.
33. Soreff J, Blomback M. Arthropathy in children with severe hemophilia A. Acta Paediatr Scand 1980; 69: 667-73.
34. Gringeri A, von Mackensen S, Auerswald G et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia 2004; 10(Suppl. 1): 26-33.
35. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
36. Valentino LA, Giangrande P, Epstein JD, Xiong Y, Ito D, Li-McLeod J. The relationship between specific annual bleed rates and health outcomes among children with severe hemophilia A. J Thromb Haemost 2013; 11: Abstract PB3.38-2.
37. Shapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: E105.
38. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13(Suppl. 2): 16-22.
39. Santagostino E, Mancuso ME. Prevention of arthropathy in haemophilia: prophylaxis. Haemophilia 2008; 14(Suppl. 6): 16-9.
40. Richards M, Williams M, Chalmers E et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.
41. Valentino LA, Hakobyan N, Enockson C et al. Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia 2012; 18: 310-8.
42. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
43. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
44. Marcucci G, Cheng J, Oldenburg J et al. Meta-analysis of post authorization safety studies (PASS): worldwide post-marketing surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/albumin-free method of rAHF-PFM. J Thromb Haemost 2013; 11: Abstract PO 148.
45. Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 2012; 10: 169-73.
46. Laine C, Davidoff F. Patient-centered medicine. A professional evolution. JAMA 1996; 275: 152-6.